Drug Trial Radar · NCT07723248
A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
600
Planned (sponsor's estimate)
Start
Aug 3, 2026
Primary completion
Mar 2028
Study completion Sep 2030
Sponsor
- Lead sponsor
- ORIC PharmaceuticalsIndustry
- Sponsor type
- Industry
- Collaborators
- Bayer
- First posted
- Jul 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Himalayas-1 is a randomized, open-label, global, multicenter phase 3 study evaluating whether the combination of rinzimetostat with darolutamide is more effective compared to physician's choice of control; ARPI (darolutamide or enzalutamide) or docetaxel for treating patients with metastatic castration resistant prostate cancer (mCRPC) who were previously treated with abiraterone acetate. The primary objective of this study is to demonstrate superiority in radiographic progression free survival (rPFS) of the investigational arm of rinzimetostat + darolutamide combination versus physician's choice of control: ARPI (darolutamide or enzalutamide) or docetaxel.
Conditions
- Metastatic Castration Resistant Prostate Cancer
Interventions
RinzimetostatDrug
400 mg once daily (QD)
DarolutamideDrug
600 mg twice daily (BID)
EnzalutamideDrug
160 mg once daily (QD)
DocetaxelDrug
75 mg/m2 intravenously (IV) every 21 days for up to 10 cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- Radiographic Progression Free Survival assessed by blinded independent central review (BICR) per RECIST v1.1 and Prostate Cancer Clinical Trials Working Group 3 (PCWG3)Time frame: Randomization up to ~2 years
Locations
15 sites in 2 countries. Site status is shown where the registry gives one.
Oncura Health
Glendale, California · Recruiting
SSAK Partners, LLC
Coral Springs, Florida · Recruiting
First Urology PSC
Jeffersonville, Indiana · Recruiting
Cancer And Hematology Centers Of Western Michigan
Holland, Michigan · Recruiting
Urology Specialists of the Carolinas - University Place
Charlotte, North Carolina · Recruiting
Gabrail Cancer Center Research
Canton, Ohio · Recruiting
MidLantic Urology LLC
Bala-Cynwyd, Pennsylvania · Recruiting
Keystone Urology Specialists
Lancaster, Pennsylvania · Recruiting
Carolina Urologic Research Center
Myrtle Beach, South Carolina · Recruiting
Urology Associates
Nashville, Tennessee · Recruiting
Urology Clinics Of North Texas
Dallas, Texas · Recruiting
Urology Partners of North Texas (UPNT)
Fort Worth, Texas · Recruiting
Houston Metro Urology (HMU)
Houston, Texas · Recruiting
Summit Urology
Murray, Utah · Recruiting
BRCR Global (Network)
San Juan, Puerto Rico · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.